Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022
Third quarter (July-September 2022) · Operating profit/loss totaled SEK -7,028,100 (-6,753,799). · Loss for the period totaled SEK -7,118,476 (-6,753,799). · Cash flow from operating activities totaled SEK -4,875,926 (-13,418,888). · Earnings per share before dilution totaled SEK -0.36 (-0.34) Earnings per share after dilution amounted to SEK -0.36 (-0.35). Period (January-September 2022) · Operating profit/loss totaled SEK -15,410,951 (-10,977,101). · Loss for the period totaled SEK -15,540,291 (-10,978,176). · Cash flow from operating activities totaled